| Date |
Announcements
|
Attachment |
| Nov 22, 2006 |
Avexa gets all clear from Phase 1 Cardiac Safety Trial |
 PDF file - 64.51 KB
|
| Nov 9, 2006 |
Avexa Antibiotic is Active in Animal Proof of Concept Study |
PDF file - 65.08 KB
|
| Oct 27, 2006 |
Avexa Announces 2006 Share Purchase Plan |
PDF file - 159.83 KB
|
| Oct 24, 2006 |
AGM Chairman's Address 2006 |
PDF file - 61.03 KB
|
| Oct 24, 2006 |
AGM CEO presentation 2006 |
PDF file - 104.33 KB
|
| Sep 25, 2006 |
Notice of Meeting 2006 |
PDF file - 29.37 KB
|
| Sep 14, 2006 |
Update on Apricitabine's Clinical Development |
PDF file - 65.92 KB
|
| Aug 8, 2006 |
Avexa's strong financial position provides foundation for promising year ahead |
PDF file - 25.51 KB
|
| Jul 24, 2006 |
Update on Apricitabine's Development |
PDF file - 26.58 KB
|
| May 10, 2006 |
Avexa's Capital Raising Oversubscribed |
PDF file - 49.22 KB
|
| Apr 3, 2006 |
Prospectus for Non-Renounceable Rights Issue 3 April 2006 |
PDF file - 144.25 KB
|
| Apr 3, 2006 |
Avexa secures US placement and announces rights issue in a $14.4 million capital raising |
PDF file - 45.63 KB
|
| Apr 3, 2006 |
Appendix 3B New Issue Announcement 3 April 2006 |
PDF file - 79.03 KB
|
| Mar 15, 2006 |
Avexa ramps up Phase 111 preparations for AVX754 |
PDF file - 20.38 KB
|
| Feb 13, 2006 |
Avexa announces Half Yearly Results |
PDF file - 60.15 KB
|
| Feb 8, 2006 |
Avexa signs exclusive licence agreement with MNLpharma |
PDF file - 58.15 KB
|
| Jan 25, 2006 |
Appendix 4C Quarterly Report |
PDF file - 62.12 KB
|
|
Annual Report 2006 |
PDF file - 347.12 KB
|
Our attachments use Adobe PDF which means you may have to use an Acrobat Reader. You can
